Direct cardiac effects of SGLT2 inhibitors
Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
JP Curtain, KF Docherty, PS Jhund… - European heart …, 2021 - academic.oup.com
Aims The aim of this study was to examine the effect of dapagliflozin on the incidence of
ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection …
ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection …
Mechanisms underlying antiarrhythmic properties of cardioprotective agents impacting inflammation and oxidative stress
K Andelova, BS Bacova, M Sykora, P Hlivak… - International Journal of …, 2022 - mdpi.com
The prevention of cardiac life-threatening ventricular fibrillation and stroke-provoking atrial
fibrillation remains a serious global clinical issue, with ongoing need for novel approaches …
fibrillation remains a serious global clinical issue, with ongoing need for novel approaches …
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT …
A Cesaro, F Gragnano, P Paolisso… - Frontiers in …, 2022 - frontiersin.org
Background Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant
cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM). They …
cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM). They …
SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta‐analysis of randomized clinical trials
CP Oates, CG Santos‐Gallego, A Smith… - Journal of …, 2023 - Wiley Online Library
Introduction Multiple randomized controlled trials have demonstrated sodium‐glucose
cotransporter‐2 inhibitors (SGLT2i) decrease the composite endpoint of cardiovascular …
cotransporter‐2 inhibitors (SGLT2i) decrease the composite endpoint of cardiovascular …
Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a
J Goerg, M Sommerfeld, B Greiner, D Lauer… - International Journal of …, 2021 - mdpi.com
The effects of the selective sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin
in low dose on cardiac function were investigated in normoglycemic rats. Cardiac …
in low dose on cardiac function were investigated in normoglycemic rats. Cardiac …
Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
AJ Scheen - Diabetes & Metabolism, 2022 - Elsevier
Type 2 diabetes is associated with a higher risk of cardiac arrhythmias, especially in
presence of cardiovascular disease and/or heart failure. Even if atrial fibrillation/flutter …
presence of cardiovascular disease and/or heart failure. Even if atrial fibrillation/flutter …
Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias
AA Manolis, TA Manolis, H Melita… - Trends in Cardiovascular …, 2023 - Elsevier
The introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors as a new and
effective class of therapeutic agents for type 2 diabetes (T2D) preventing the reabsorption of …
effective class of therapeutic agents for type 2 diabetes (T2D) preventing the reabsorption of …
Is there a role for SGLT2 inhibitors in patients with end-stage kidney disease?
Purpose of Review Chronic kidney disease and end-stage kidney disease (ESKD) are well-
established risk factors for cardiovascular disease (CVD), the leading cause of mortality in …
established risk factors for cardiovascular disease (CVD), the leading cause of mortality in …
Effect of sodium-glucose co-transporter protein 2 inhibitors on arrhythmia in heart failure patients with or without type 2 diabetes: a meta-analysis of randomized …
Z Yin, H Zheng, Z Guo - Frontiers in Cardiovascular Medicine, 2022 - frontiersin.org
Aim Arrhythmic events such as atrial fibrillation (AF) are tightly associated with an increased
risk of heart failure (HF). Previous studies have shown inconsistent results regarding the …
risk of heart failure (HF). Previous studies have shown inconsistent results regarding the …